SCHEMBL4036707

SCHEMBL4036707

O=C(NC1CCCCC1)C(C1CCCCC1)C1(c2cccnc2)Nc2cc(F)c(Cl)cc2N1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
C3AR1 Q16581 8/20 0.41
CYP3A4 P08684 2/20 0.41
KCNH2 Q12809 2/20 0.41
NR1H4 Q96RI1 2/20 0.41
POLB P06746 1/20 0.40
MDM2 Q00987 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 1/20 0.39
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CNR1 P21554 1/20 0.37
WNT1 P04628 1/20 0.36
DYRK1A Q13627 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4036896 0.89 NR1H4 (0.42) CYP3A4KCNH2NR1H4POLBSMN1; SMN2
SCHEMBL4034374 0.85 KCNH2 (0.48) CYP3A4KCNH2NR1H4POLBSMN1; SMN2
SCHEMBL4038655 0.85 KCNH2 (0.48) CYP3A4KCNH2NR1H4POLBSMN1; SMN2
SCHEMBL4036578 0.85 KCNH2 (0.48) CYP3A4KCNH2NR1H4POLBSMN1; SMN2
SCHEMBL4038777 0.85 CYP3A4 (0.42) CYP3A4KCNH2NR1H4POLBSMN1; SMN2
SCHEMBL4039537 0.85 KCNH2 (0.48) CYP3A4KCNH2NR1H4POLBSMN1; SMN2
SCHEMBL4036376 0.85 KCNH2 (0.48) CYP3A4KCNH2NR1H4POLBSMN1; SMN2
SCHEMBL4042942 0.85 CYP3A4 (0.42) CYP3A4KCNH2NR1H4POLBSMN1; SMN2
SCHEMBL4041039 0.83 CYP3A4 (0.41) C3AR1CYP3A4KCNH2NR1H4SMN1; SMN2
SCHEMBL4035068 0.81 NPC1 (0.46) CYP3A4KCNH2NR1H4SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed